Correlation between serum levels of RANKL with osteoporosis in patients with beta thalassemia major

authors:

avatar Fatemeh Jafari , avatar Azita Azarkeivan , avatar Davod Bashash , avatar Ali Akbar Khadem Maboodi , avatar mohsen hamidpour ORCID , *

Koomesh: Vol.21, issue 1; 150-154
published online: March 05, 2019
article type: Research Article
received: April 02, 2018
accepted: September 05, 2018

how to cite: Jafari F, Azarkeivan A, Bashash D, Khadem Maboodi A A, hamidpour M. Correlation between serum levels of RANKL with osteoporosis in patients with beta thalassemia major. koomesh. 2019;21(1):e153051. 

Abstract

Introduction: Osteoporosis is a major problem in patients with B-thalassemia major. Osteoclasts hyperactivity, which increases serum levels of receptor activator of nuclear factor kappa-Β ligand (RANKL), plays an important role in the pathogenesis of osteoporosis in these patients. The aim of this study was to study the relationship between serum levels of RANKL and osteoporosis in patients with beta thalassemia major. Materials and Methods: 52 patients with beta thalassemia major and 22 people with thalassemia minor without any osteoporosis symptoms as controls were entered the study.  Six ml of peripheral blood was obtained for hematologic and serum RANKL measurements. Results: The mean of bone mineral density in patients were 0.57 ± 0.3 and 0.69 ± 0.11 in femur and vertebra, respectively.  There were significant differences between hematologic parameters of patients and controls. The mean of patient’s serum RANKL level was 198.4pg/mL and in controls was 112.25pg/mL. There was a correlation between decrease of femur BMD (p

References

  • 1.

    Jalali H, Mahdavi MR, Roshan P, Kosaryan M, Karami M, Mahdavi M. Alpha thalassemia gene mutations in neonates from Mazandaran, Iran, 2012. Hematology 2014; 19: 192-195. (Persian).

  • 2.

    Moradi G, Ghaderi E. Chronic disease program in Iran: Thalassemia control program. Chronic Dis J 2013; 1: 98-106.

  • 3.

    Galehdari H, Salehi B, Bijan Keikhaei S, Zandian KM, Pedram M. Comprehensive spectrum of the -thalassemia mutations in Khuzestan, Southwest Iran. Hemoglobin 2010; 34: 461-468.

  • 4.

    Prabhu R, Prabhu V. Iron overload in beta thalassemia: a review. J Biosci Tech 2009; 1: 20-31.

  • 5.

    Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis2010; 5: 11-18.

  • 6.

    McLaren CE, Barton JC, Adams PC, Harris EL, Acton RT, Press N, et al. Hemochromatosis and IronOverload Screening (HEIRS) study design for an evaluation of 100,000 primary care-basedadults. Am J Med Sci 2003; 325: 53-62.

  • 7.

    Kattamis AC, Antoniadis M, Manoli I, Kitra V, Petropoulos D, Grafakos S. Endocrine problems in ex-thalassemic patients. Transfus Sci2000; 23: 251-252.

  • 8.

    Mohammadian S, Bazrafshan U, Sadeghi-Nejad A. Endocrine gland abnormalities in thalassemia major: a brief review. J Pediatr Endocrinol Metab2003; 16: 957-964.

  • 9.

    Khashayar P, Aghaei Meybodi HR, Rezai Homami M, Heshmat R, Larijani B. The prevalence of osteoporosis in an Iranian population. J Clin Densitometr 2010; 13: 112-119. (Persian).

  • 10.

    Salehi Abari I, Khazaeli S, Najafizadeh R, Malekpour M. High prevalence of low bone density in young Iranian healthy individuals.Clin Rheumatol2009; 28: 173-177.

  • 11.

    De Sanctis V, Soliman AT, Elsedfy H, Yassin M, Canatan D, Kilinc Y, et al. Osteoporosis in thalassemia major: an update and the I-CET 2013 recommendations for surveillance and treatment. Pediatr Endocrinol Rev 2013; 11: 167-180.

  • 12.

    Rossi F, Perrotta S, Bellini G, Luongo L, Tortora C, Siniscalco D, et al. Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels. Haematologica 2014; 99: 1876-1884.

  • 13.

    Voskaridou E, Terpos E.New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 2004; 127: 127-139.

  • 14.

    Skordis N, Efstathiou E, Kyriakou A, Toumba M. Hormonal dysregulation and bones in thalassaemia--an overview.Pediatr Endocrinol Rev 2008; 6: 107-115.

  • 15.

    Olivieri NF, Koren G, Harris J, Khattak S, Freedman MH, Templeton DM, et al. Growth failure and bony changes induced by deferoxamine. Am J Pediatr Hematol Oncol 1992; 14: 48-56.

  • 16.

    Toumba M, Skordis N. Osteoporosis syndrome in thalassaemia major: an overview. J Osteoporos 2010; 2010: 1-8.

  • 17.

    Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002; 22: 549-553.

  • 18.

    Saki N, Abroun S, Salari F, Fakher R, Shahjahani M, Mohammadi-Asl J. Molecular aspects of bone resorption in -thalassemia major. Cell J (Yakhteh) 2015; 17: 193-199. (Persian).

  • 19.

    Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, Prescott E, Hoffbrand AV, Wonke B. High prevalence of low bone mass in thalassaemia major. Br J Haematol 1998; 103: 911-915.

  • 20.

    Ilich JZ, Kerstetter JE. Kerstetter, Nutrition in bone health revisited: a story beyond calcium. J Am Coll Nutr 2000; 19: 715-737.

  • 21.

    WHO study group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis.WHO technical report series 843, 1994.Geneva. http://www.who.int/iris/handle/10665/39142.

  • 22.

    Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M, et al. Osteoprotegerin and RANKL in the pathogenesis of thalassemia induced osteoporosis: new pieces of the puzzle. J Bone Miner Res 2004; 19: 722-727.

  • 23.

    Morabito N, Catalano A, Gaudio A, Morini E, Bruno LM, Basile G, et al. Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis. J Bone Miner Metab 2016; 34: 540-546.

  • 24.

    Salah H, Atfy M, Fathy A, Atfy M, Mansor H, Saeed J. The clinical significance of OPG/sRANKL ratio in thalassemia patients suffering from osteopenia or osteoporosis in egyptianpatients. Immunol Invest 2010; 39: 820-832.

  • 25.

    Angelopoulos NG, Goula A, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, et al. Circulating osteoprotegerin and receptor activator of NF-B ligand system in patients with -thalassemia major. J Bone Miner Metab 2007; 25(1): 60-67.

  • 26.

    Hamidi Z, Sedaghat M, Mortaz Hejri S, Larijani B. Defining cut-off values for the diagnosis of osteoporosis in postmenopausal women by quantitative ultrasonography of the phalanx. Gynecol Endocrinol2008; 24: 546-554.

  • 27.

    Wong P, Fuller PJ, Gillespie MT, Milat F. Bone disease in thalassemia: amolecular and clinical overview. Endocr Rev 2016; 37: 320-346.

  • 28.

    Kwiatkowski JL. Management of transfusional iron overload - differential properties and efficacy of iron chelating agents. J Blood Med 2011;2: 135-149.

  • 29.

    Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl Pharmacol 2005; 202: 199-211.

  • 30.

    Khosla S. Minireview: The opg/rankl/rank system. Endocrinology 2001; 142: 5050-5055.

  • 31.

    Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKLRANK signaling in osteoclastogenesis and bone disease.Trends Mol Med2006; 12: 17-25.

  • 32.

    Jeney V. Clinical impact and cellular mechanisms of iron overload-associated bone loss.Front Pharmacol2017; 8: 1-11.